GLPG Stock Analysis: Galapagos | AS
Biotechnology | AS, Netherlands | Market Cap: 1.554m EUR | 12M Return: 8.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.05M
Qual. Beats: 1
Rev. Trend: 90.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Galapagos NV is a Belgian biotechnology firm specializing in the development of oncology and immunology therapies for the European and U.S. markets. The company’s current clinical pipeline centers on CAR-T cell therapies and small molecule inhibitors targeting autoimmune conditions and hematological malignancies.
The business model relies heavily on strategic partnerships, most notably a long-term collaboration with Gilead Sciences to advance its research and development platform. In the biotechnology sector, point-of-care manufacturing models for CAR-T therapies aim to reduce vein-to-vein time and logistical costs compared to centralized production.
Key clinical assets include GLPG3667 for lupus and dermatomyositis, alongside CD19 and BCMA CAR-T candidates currently in Phase 1/2 trials for lymphoma and multiple myeloma. For a deeper look at the fundamental metrics of this small-cap biotech, consider reviewing the data on ValueRay.
- CAR-T pipeline clinical trial data readouts drive valuation
- Point-of-care manufacturing platform scales to reduce oncology treatment costs
- Gilead Sciences collaboration agreement provides long-term capital and commercial stability
- Strategic pivot to oncology acquisitions utilizes substantial cash reserves
| Net Income: 488.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA -1.16 > 1.0 |
| NWC/Revenue: 283.6% < 20% (prev 1.05k%; Δ -769.6% < -1%) |
| CFO/TA -0.09 > 3% & CFO -292.4m > Net Income 488.8m |
| Net Debt (-2.98b) to EBITDA (432.1m): -6.89 < 3 |
| Current Ratio: 30.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.0m) vs 12m ago 4.82% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 28.23% > 50% (prev 7.17%; Δ 21.07% > 0%) |
| Interest Coverage Ratio: 171.3 > 6 (EBIT TTM 380.2m / Interest Expense TTM 2.22m) |
| A: 0.88 (Total Current Assets 3.06b - Total Current Liabilities 100.4m) / Total Assets 3.37b |
| B: 0.07 (Retained Earnings 228.3m / Total Assets 3.37b) |
| C: 0.10 (EBIT TTM 380.2m / Avg Total Assets 3.70b) |
| D: 27.33 (Book Value of Equity 3.25b / Total Liabilities 119.1m) |
| Altman-Z'' = 35.36 = AAA |
| DSRI: 0.18 (Receivables 54.0m/83.5m, Revenue 1.04b/288.2m) |
| GMI: 0.86 (GM 84.02% / 98.01%) |
| AQI: 0.64 (AQ_t 0.07 / AQ_t-1 0.11) |
| SGI: 3.62 (Revenue 1.04b / 288.2m) |
| TATA: 0.23 (NI 488.8m - CFO -292.4m) / TA 3.37b) |
| Beneish M = -2.14 (Cap -4..+1) = BB |
As of July 08, 2026, the stock is trading at EUR 26.40 with a total of 69,144 shares traded. Over the past week, the price has changed by +2.72%, over one month by +8.37%, over three months by +7.14% and over the past year by +8.20%.
Current recommended Stop Loss: 25.50 (which is 3.4% or 1.3 ATR below the current price).
Galapagos has no consensus analysts rating.
P/E Trailing = 3.1822
P/E Forward = 357.1429
P/S = 1.4887
P/B = 0.525
Revenue TTM = 1.04b EUR
EBIT TTM = 380.2m EUR
EBITDA TTM = 432.1m EUR
Long Term Debt = 4.85m EUR (estimated: total debt 6.43m - short term 1.58m)
Short Term Debt = 1.58m EUR (from shortTermDebt, last quarter)
Debt = 6.43m EUR (from shortLongTermDebtTotal, last quarter) (leases 6.43m already included)
Net Debt = -2.98b EUR (calculated: Debt 6.43m - CCE 2.98b)
Enterprise Value = 1.55b EUR (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 171.3 (Ebit TTM 380.2m / Interest Expense TTM 2.22m)
EV/FCF = -5.16x (Enterprise Value 1.55b / FCF TTM -301.1m)
FCF Yield = -19.38% (FCF TTM -301.1m / Enterprise Value 1.55b)
FCF Margin = -28.85% (FCF TTM -301.1m / Revenue TTM 1.04b)
Net Margin = 46.83% (Net Income TTM 488.8m / Revenue TTM 1.04b)
Gross Margin = unknown ((Revenue TTM 1.04b - Cost of Revenue TTM 20.8m) / Revenue TTM)
Tobins Q-Ratio = 0.46 (Enterprise Value 1.55b / Total Assets 3.37b)
Interest Expense / Debt = 34.50% (Interest Expense 2.22m / Debt 6.43m)
Taxrate = 0.50% (70.0k / 14.0m)
NOPAT = 378.3m (EBIT 380.2m * (1 - 0.50%))
Current Ratio = 30.48 (Total Current Assets 3.06b / Total Current Liabilities 100.4m)
Debt / Equity = 0.00 (Debt 6.43m / totalStockholderEquity, last quarter 3.25b)
Debt / EBITDA = -6.89 (Net Debt -2.98b / EBITDA 432.1m)
Debt / FCF = 9.88 (negative FCF - burning cash) (Net Debt -2.98b / FCF TTM -301.1m)
Total Stockholder Equity = 2.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.22% (Net Income 488.8m / Total Assets 3.37b)
RoE = 16.88% (Net Income TTM 488.8m / Total Stockholder Equity 2.90b)
RoCE = 13.11% (EBIT 380.2m / Capital Employed (Equity 2.90b + L.T.Debt 4.85m))
RoIC = 11.74% (NOPAT 378.3m / Invested Capital 3.22b)
WACC = 6.92% (E(1.55b)/V(1.56b) * Re(6.81%) + D(6.43m)/V(1.56b) * Rd(34.50%) * (1-Tc(0.01)))
Discount Rate = 6.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -2.52 | Cagr: 2.07%
[DCF] Fair Price = unknown (Cash Flow -301.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.51 | # QB: 1
Revenue Correlation: 90.42 | Revenue CAGR: 115.4% | SUE: -0.06 | # QB: 0
EPS current Quarter (2026-03-31): EPS=-0.51 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS next Quarter (2026-06-30): EPS=-0.43 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-3.05 | Chg30d=+28.24% | Revisions=-50% | GrowthEPS=-129.9% | GrowthRev=-75.5%
EPS next Year (2027-12-31): EPS=-3.91 | Chg30d=+0.00% | Revisions=-40% | GrowthEPS=-28.2% | GrowthRev=-40.3%
[Analyst] Revisions Ratio: -62% (up=0, down=5)